Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Tarcocimab · 1 trial · 1 indication
Early Treatment Diabetic Retinopathy Diabetic Retinopathy Severity Scale (ETDRS DRSS), on a scale from 10 to 90, where lower scores represent better outcomes.
| Arm | Type | Description |
|---|---|---|
| Tarcocimab 5 mg (Treatment Group A) | EXPERIMENTAL | Tarcocimab 5 mg via intravitreal injection at Day 1, Week 4, Week 8, Week 20, and Week 44. |
| Treatment Group B | SHAM_COMPARATOR | Sham injection on the same schedule as Treatment Group A |
| Name | Type | Description |
|---|---|---|
| Tarcocimab | DRUG | Intravitreal injection |
| Sham injection | OTHER | The sham injection is a procedure that mimics an intravitreal injection. It involves pressing the blunt end of an empty syringe (without a needle) against the anesthetized eye. It is performed to maintain masking of the study. |
Inclusion Criteria: * Signed informed consent prior to participation in the study. * Type 1 or 2 diabetes mellitus and HbA1c of ≤12%. * DR in the Study Eye (DRSS as determined by the reading center based on color fundus photographs), who have not previously received intravitreal medications for DR ...
Tarcocimab is an investigational small molecule being developed for diabetic retinopathy, a complication of diabetes that affects the retina. It is administered as an intravitreal injection and is currently in Phase 3 clinical development. The drug is being studied to evaluate its efficacy and safety compared with sham treatment in participants with diabetic retinopathy.
Tarcocimab is being developed by Kodiak Sciences Inc, a biopharmaceutical company traded on the NASDAQ under the ticker symbol KOD. The company is conducting clinical trials to evaluate the drug's potential as a treatment for diabetic retinopathy.
Tarcocimab is in Phase 3 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. A Phase 3 trial has been completed to evaluate its efficacy and safety in patients with diabetic retinopathy.
Tarcocimab has one completed Phase 3 clinical trial registered as NCT06270836. The study evaluated the efficacy and safety of tarcocimab compared with sham treatment in 255 participants with diabetic retinopathy. The trial was randomized, double-blind, and sham-controlled, and was conducted in the United States and Puerto Rico.
Yes, Tarcocimab is also known as Tarcocimab Tedromer. The clinical trial NCT06270836 refers to the drug as Tarcocimab Tedromer in its title. Both names refer to the same investigational drug being developed by Kodiak Sciences for diabetic retinopathy.